文献速递脑血管病外科神经重症

常染色体显性多囊肾病患者无症状颅内未破裂动脉瘤的风险因素:谁需要筛查?系统综述与Meta分析

Risk factors for unruptured intracranial aneurysms in asymptomatic patients with autosomal dominant polycystic kidney disease: who needs screening? A systematic review and meta-analysis.
PubMed 文献 · J Neurosurg · 2025-02-14

该系统综述与Meta分析纳入24项观察性研究共5907例常染色体显性多囊肾病(ADPKD)患者,评估筛查中颅内动脉瘤(IA)检出的风险因素。ADPKD患者IA总体患病率为12.6%;女性、IA或蛛网膜下腔出血(SAH)家族史、SAH家族史、慢性肾脏病(CKD)3期及以上、高血压与未破裂IA检出风险显著升高相关。作者认为具有上述风险因素的患者可能从早期筛查中获益。

要点

  • ADPKD患者筛查中IA总体患病率为12.6%。
  • 女性、IA或SAH家族史、CKD≥3期、高血压与未破裂IA检出风险升高相关。
  • 年龄>45岁、ADPKD家族史、吸烟、肝囊肿与IA检出无显著关联。

核心结论

  • Meta分析结果提示,女性、有IA或SAH家族史、高血压或中重度CKD的ADPKD患者在筛查中检出未破裂IA的风险升高。
  • 作者认为具有这些风险因素的ADPKD患者可能从治疗早期或诊断时即进行IA筛查中获益,即使神经系统无症状。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Google Scholar、Scopus、Web of Science、Cochrane系统综述数据库及ClinicalTrials.gov截至2023年8月前的研究。
  • 纳入24项观察性研究,共5907例ADPKD患者,采用随机效应模型进行Meta分析,并使用纽卡斯尔-渥太华量表评估偏倚风险。

主要发现

  • ADPKD患者筛查中IA总体患病率为12.6%。
  • 女性与未破裂IA检出风险升高相关(18项研究,OR 1.63,95%CI 1.37-1.94,I²=0%)。
  • IA或SAH家族史与未破裂IA检出风险升高相关(12项研究,OR 2.17,95%CI 1.68-2.81,I²=0%)。
  • SAH家族史与未破裂IA检出风险升高相关(3项研究,OR 2.67,95%CI 1.25-5.71,I²=66.0%)。
  • CKD 3期及以上与未破裂IA检出风险升高相关(4项研究,OR 2.55,95%CI 1.84-3.54,I²=0%);高血压与未破裂IA检出风险升高相关(13项研究,OR 1.41,95%CI 1.04-1.91,I²=34%)。

关键数值与推荐

  • 年龄>45岁、ADPKD家族史、吸烟状态及肝囊肿存在在本次Meta分析中未达到统计学显著的风险因素。

临床怎么用

  • 作者认为,具有女性、IA或SAH家族史、高血压或中重度CKD的ADPKD患者可能从治疗早期或诊断时即进行IA筛查中获益,即使神经系统无症状。

局限性

  • SAH家族史分析的异质性I²=66.0%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with autosomal dominant polycystic kidney disease (ADPKD) have been identified to have a significantly increased risk of developing intracranial aneurysms (IAs). These patients are diagnosed at younger ages and are also at increased risk for IA rupture. The objective of this systematic review and meta-analysis was to identify risk factors associated with IA detection during screening of asymptomatic ADPKD patients. METHODS: The authors searched for studies reporting the prevalence of IA among patients with ADPKD screened using MRA, CTA, or DSA on PubMed, Embase, Google Scholar, Scopus, Web of Science, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov prior to August 2023 by using individualized standardized search strategies. Eligibility of all retrieved studies was assessed according to the PRISMA guidelines. Risk of bias of the included observational studies was assessed using the Newcastle-Ottawa Scale. Meta-analysis was performed using a random-effects model. RESULTS: Twenty-four observational studies involving 5907 patients with ADPKD were identified for quantitative analysis. The authors observed an overall prevalence of IA of 12.6%. They identified several risk factors for IA with statistically significantly increased odds for unruptured IA (UIA) detection, including female sex (18 studies, OR 1.63, 95% CI 1.37-1.94, I2 = 0%), family history of either IA or subarachnoid hemorrhage (SAH) (12 studies, OR 2.17, 95% CI 1.68-2.81, I2 = 0%), family history of SAH (3 studies, OR 2.67, 95% CI 1.25-5.71, I2 = 66.0%), stage 3 or greater chronic kidney disease (CKD) (4 studies, OR 2.55, 95% CI 1.84-3.54, I2 = 0%), and hypertension (13 studies, OR 1.41, 95% CI 1.04-1.91, I2 = 34%). Age > 45 years, family history of ADPKD, smoking status, and presence of liver cysts did not reach statistical significance as risk factors during this meta-analysis. CONCLUSIONS: The results of the authors' meta-analysis suggest increased risk of UIA detection in screening of ADPKD patients who are female, have a family history of IA or SAH, have hypertension, or have moderate or more severe CKD. Given the increased prevalence of IA in ADPKD patients with these risk factors, these patients may stand to benefit from screening for IA early in treatment or at time of diagnosis, even if neurologically asymptomatic.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Nguyen BA, Halpin B, Olson V, et al. Risk factors for unruptured intracranial aneurysms in asymptomatic patients with autosomal dominant polycystic kidney disease: who needs screening? A systematic review and meta-analysis. J Neurosurg. 2025. PMID: 39951701. doi:10.3171/2024.9.JNS241175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。